Induction therapy for patients with multiple sclerosis: Why? When? How?

CNS Drugs

Volumn 27, Issue 6, 2013, Pages 403-409

  Edan, Gilles ^a   Le Page, Emmanuelle ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB;

AMENORRHEA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CONGESTIVE HEART FAILURE; DISEASE ACTIVITY; DISEASE CONTROL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG THERAPY; FEMALE STERILITY; GLOMERULOPATHY; GRAVES DISEASE; HUMAN; IMMUNOTHERAPY; INDUCTION THERAPY; LEUKEMIA; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; THROMBOCYTOPENIC PURPURA;

DRUG ADMINISTRATION SCHEDULE; HUMANS; INDUCTION CHEMOTHERAPY; INTERFERON-BETA; MAINTENANCE CHEMOTHERAPY; MITOXANTRONE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY AS TOPIC; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84879310972     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0065-y     Document Type: Review

References (27)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-78.
2. Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci. 2008;29:S253-5.
3. Reickmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009;277(S1):S42-5.
4. Panitch H, Miller A, Paty D, et al. North American Study Group on interferon beta 1b in secondary progressive MS: result from a 3 year controlled study. Neurology. 2004;63:1788-95.
5. Coles AJ, Cox E, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253:98-108.
6. Leray E, Yaouanq J, Le Page E, et al. Evidence of a two stage disability progression in multiple sclerosis. Brain. 2010;133:1900-13.
7. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study. 10. Relapses and long-term disability. Brain. 2010;133:1914-29.
8. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808-17.
9. Weiner HL. The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease? Ann Neurol. 2009;65:239-48.
10. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62:112-8.
11. Le Page E, Leray E, Taurin G. etal. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79:52-6.
12. Edan G, Comi C, Le Page E, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82:1344-50.
13. Vollmer T, Panitch H, Bar-Or A. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14(5):663-70.
14. Le Page E, Leray E, Edan G. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler. 2011;17:867-75.
15. Stroet A, Hemmelmann C, Starck M, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012;5(2):75-9.
16. Martinelli V, Cocco E. Capra R et al Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011;77(21):1887-95.
17. Meistrich ML, Wilson G, Mathur K, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol. 1997;15:3488-95.
18. Polman Ch, O'Connor PW, Havrdora E, et al. A randomized, placebo controlled trial of natalizumab of relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
19. Hutchinson M, Kappos L, Calabresi P, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405-15.
20. Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multiple leukoencephalopathy in patients treated with natalizumab. Mult Scler J. 2012;18(2):143-52.
21. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci. 2011;308:98-102.
22. Sempere AP, Martin-Medina P, Berenguer-Ruiz L, et al. Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand. 2013. doi: 10.1111/ane.12082.
23. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-801.
24. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet. 2012;380:1819-28.
25. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized phase 3 trial. Lancet. 2012;380:1829-39.
26. Coles AJ, Cox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78:1069-78.
27. Cossburn M, Pace AA, Jones JJ, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77:573-9.